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Background: Nicotinamide phosphoribosyltransferase (NAMPT) is the limiting enzyme in one of pathways of
synthesis of Nicotinamide Adenine Dinucleotide, a redox coenzyme. NAMPT is considered as an insulin-mimetic
factor and a potential regulatory factor in inflammatory and immune processes. Associations of circulating
NAMPT levels with cardiovascular disease (CVD) and insulin resistance have been reported. We investigated
association of circulating NAMPT levels and the rs9770242 NAMPT gene polymorphism with coronary artery
disease (CAD).
Methods: We studied 594 Brazilian subjects undergoing a coronary angiography (49% of whom had type 2
diabetes). CAD, defined as stenosis greater than 50% in one major coronary vessel or branch, was observed in
68% of subjects. Genetic studies were also performed in 858 North-American Non-Hispanic White subjects with
type 2 diabetes (49% with CAD).
Results: We observed an interaction between glycemic and CAD status on the comparison of NAMPT levels
by CAD status. NAMPT levels were higher in type 2 diabetic patients with CAD as compared to those without
CAD: 5.27 ± 2.93 ng/ml vs. 4.43 ± 2.94 ng/ml, p = 0.006 (mean ± SD). NAMPT levels were not significantly
different in non-diabetic subjects with or without CAD. The T-allele of rs9770242 was associated with CAD in
the Brazilian cohort (OR 1.46, 95% CI 1.06 - 2.01, p = 0.02) while no association was observed in the
North-American cohort.
Conclusions: Our data suggest that circulating NAMPT levels are associated with CAD in type 2 diabetic
patients. NAMPT rs9770242 polymorphism may be associated with CAD in some populations.
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The adipose tissue secretes several adipokines, including
adiponectin, leptin, resistin and, of more recent discov-
ery, nicotinamide phosphoribosyltransferase (NAMPT)
[1]. It was suggested that these molecules could explain,
at least in part, the link between obesity, insulin resist-
ance, beta-cell dysfunction, endothelial dysfunction, ath-
erosclerosis and cardiovascular disease (CVD) [1-6].
NAMPT, formerly known as visfatin or pre-B cell colony
enhancing factor (PBEF), is expressed throughout the body.
It is secreted mainly by adipocytes and macrophages [5],
but also by human pancreatic beta cells where its secretion
is upregulated by glucose [7]. NAMPT is the limiting en-
zyme in the mammalian salvage pathway of synthesis of
Nicotinamide Adenine Dinucleotide (NAD+), an ubiquitary
coenzyme involved in redox reactions. NAMPT is consid-
ered as an insulin-mimetic factor and a potential regulatory
factor of inflammatory and immune processes [1,5,8]. As-
sociations of circulating NAMPT levels with several in-
flammatory conditions and metabolic alterations have been
reported. For instance, some studies have shown associa-
tions of circulating levels of NAMPT with CVD, as well
as with surrogates of insulin resistance [3,9-11]. The hu-
man NAMPT gene maps to a region on chromosome
7q22.2 previously found to be linked to insulin resistance
syndrome-related phenotypes in nondiabetic Mexican-
Americans [12]. In addition, several frequent polymor-
phisms (minor allele frequency >0.05) in the NAMPT gene
were reported to be associated with a variety of physio-
logical and pathological phenotypes including obesity,
dyslipidemia, low-grade inflammation, and type 2 diabetes
[13-15]. The T-allele of the promoter variant rs9770242
was shown to be associated with higher fasting plasma glu-
cose and insulin levels [14] and with higher visceral/sub-
cutaneous ratio of NAMPT mRNA expression in adipose
tissue [15]. In different populations, this SNP is in perfect
or moderate linkage disequilibrium (LD) with other SNPs
in the 5′ region located in the putative promoter region
(−948 G >T, rs1319501) [14,15].
In the present study we investigated associations of
circulating levels of NAMPT with coronary artery dis-
ease (CAD) and related phenotypes in Brazilian subjects
with high cardiovascular risk, with or without type 2 dia-
betes. We also studied the association between the
rs9770242 SNP and CAD in this Brazilian cohort and in
an independent cohort of North-American non-Hispanic
white subjects with type 2 diabetes.
Methods
Subjects: Brazilian cohort
A total of 594 consecutive patients who underwent coron-
ary angiography at Hospital São Paulo-Brazil (UNIFESP
University Hospital) were enrolled in the present study, as
previously described [16]. In brief, subjects were 60 ±10 years old, 56.7% of them were men and 49% had type 2
diabetes. Patients were referred to cardiac catheterization
by their physicians for reasons such as stable angina, posi-
tive stress test, non-ST-elevation acute coronary syn-
drome. For the purpose of this study, CAD was defined as
any stenosis greater than 50% in at least one major coron-
ary vessel or branch observed during coronary angiog-
raphy. Diabetes mellitus was defined according to the
American Diabetes Association criteria [17]. Arterial
hypertension was defined as systolic blood pressure
(SBP) ≥140 mmHg and/or diastolic blood pressure
(DBP) ≥90 mmHg, or current use of antihypertensive
medication and history of hypertension. Subjects
were considered to have dyslipidemia either if levels of
LDL-cholesterol were ≥4.14 mmol/l, HDL-cholesterol
≤1.04 mmol/l, triglycerides ≥2.26 mmol/l, or in the pre-
sence of use of lipid lowering medications (statin/
fibrates). Study subjects, individually and/or as a group,
had mixed ethnic background (African, Amerindian,
Asian, and European Caucasian of several different
countries of origin), reflecting the Brazilian population
[18]. All participants gave written informed consent.
The study was approved by the ethics committee of
UNIFESP.
Subjects: North-American cohort
We studied 858 Non-Hispanic white people. Clinical
characteristics of a subset of this population have been
previously described [19]. In brief, CAD positive case pa-
tients (n = 424) were a random sample of patients with
type 2 diabetes who had a stenosis greater than 50% in a
major coronary artery or a main branch, documented by
cardiac catheterization at the Beth Israel Deaconess
Medical Center (BIDMC) between 2001 and 2008.
CAD-negative controls (n = 434) were randomly selected
from among 903 Joslin patients as fulfilling the following
criteria: current age between 55 and 74 years; type 2 dia-
betes for five years or more; negative cardiovascular his-
tory and normal response to an exercise treadmill test.
The study protocol and informed consent procedures
were approved by the Joslin Committee on Human Stud-
ies and the BIDMC Committee on Clinical Investigations.
Clinical and biological procedures
In the Brazilian set, a blood sample was drawn after an
overnight fast for analysis of plasma glucose, plasma in-
sulin, HbA1c (HPLC, reference value: 4.5-6.0%), lipid
profile (total serum cholesterol, LDL-cholesterol, HDL-
cholesterol, and serum triglycerides), TSH and creatin-
ine. Glomerular filtration rate was estimated using the
Modification of Diet in Renal Disease study equation
[20]. Plasma NAMPT levels were measured using com-
mercial ELISA kits (EK-003-80, Phoenix Pharmaceuti-
cals). Intra- and interassay coefficients of variation were
Table 1 Brazilian cohort – clinical characteristics of
participants by CAD status
With CAD Without CAD p
Subjects (n) 406 188
Sex: Male (%) 63 50 0.0005
Age (y) 60 ± 11 57 ± 11 0.0001
Diabetes mellitus (%) 48 52 0.35
Fasting plasma glucose (mmol/l) 7 ± 2.78 6.39 ± 1.89 0.03
HbA1c (%) 6.8 ± 1.6 6.6 ± 1.5 0.11
BMI (kg/m2) 27.1 ± 4.6 28.0 ± 5.0 0.06
Dyslipidemia (%) 95 86 0.01
Triglycerides (mmol/l)* 1.47[1.00-1.95] 1.36[0.89-1.84] 0.0002
LDL Cholesterol (mmol/l) 2.59 ± 0.93 2.67 ± 0.88 0.40
HDL Cholesterol (mmol/l) 0.98 ± 0.28 1.09 ± 0.28 0.0001
eGFR(ml/min) 84 ± 24 89 ± 28 0.05
Hypertension (%) 91 90 0.51
Systolic BP (mmHg) 140 ± 24 136 ± 20 0.09
Diastolic BP (mmHg) 80 ± 14 79 ± 13 0.54
Tobacco smoking (%) 57 42 0.003
Data expressed in mean ± SD, except *expressed in median [interquartile
range]. CAD coronary artery disease, HbA1c glycated hemoglobin, eGFR
estimated glomerular filtration rate. Differences between groups were
assessed by Pearson’s chi squared test and ANOVA.
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Total adiponectin levels were measured in plasma sam-
ples using commercial ELISA kits (EZHADP-61 K,
Millipore, Saint Charles, MO). Intra- and interassay co-
efficients of variation were respectively 7.4% and 10.6%
(sensitivity: 0.78 ng/ml).
DNA studies
In both cohorts, DNA was extracted from peripheral
blood samples by standard procedures. The choice of
NAMPT promoter rs9770242 was based on results from
previous studies suggesting that it might modulate
NAMPT mRNA expression in visceral and subcutaneous
fat depots [15]. The SNP was evaluated using a Taqman
SNP Genotyping Assay by Applied Biosystems. Genotyp-
ing was repeated in 20% of subjects from the Brazilian
cohort using an ABI3131XL genetic analyzer; concord-
ance rate was >99% and total genotype success rate was
97%. In the North-American study, genotyping quality
was assessed by including six blinded duplicate samples
in each 96-well assay. The average agreement rate was
greater than 99%.
Statistical analyses
Differences between groups were assessed by Pearson’s chi
squared test, ANOVA and ANCOVA. Interaction between
glycemic status (type 2 diabetes: yes/no) and CAD status
in the comparison of NAMPT levels were assessed by in-
cluding in the ANCOVA model a “crossed” compound co-
variate (glycemic status/CAD status). Stratification by
glycemic status was then performed by nesting the CAD
status variable within the glycemic status variable in the
ANCOVA. This results in the computation of statistical
effects for subjects with or without diabetes separately,
and adjusted for multiple comparisons due to the stratifi-
cation by glycemic status.
Associations with CAD were assessed by logistic re-
gression analyses and odds ratios with their 95% confi-
dence interval were computed. Adjustments for clinical
and biological parameters were carried out by including
these parameters as covariates in the regressive model.
For all analyses, data were log-transformed when the
normality of the distribution was rejected by the
Shapiro-Wilk W test. The power to detect associations
of rs9770242 with CAD in both cohorts was >90%, for
odds ratio ≥1.5 and alpha = 0.05. Statistical analysis was
performed with the JMP software (SAS Institute Inc.,
Carey, NC).
Results
Plasma NAMPT levels and CAD
The coronary angiogram was positive for CAD in 68% of
subjects in the Brazilian cohort. Clinical characteristics
of subjects with or without CAD are shown in Table 1.We observed an interaction between glycemic and CAD
status on the comparison of plasma NAMPT levels by
CAD status (p = 0.003 for the interaction). Plasma
NAMPT levels were higher in type 2 diabetic patients
with CAD as compared to those without CAD: 5.27 ±
2.93 ng/ml vs. 4.43 ± 2.94 ng/ml, p = 0.006 (mean ± SD,
ANCOVA with log-transformed data, adjusted for age
and sex). The difference between groups remained sig-
nificant when the comparison was further adjusted for
BMI, dyslipidemia, arterial hypertension and tobacco
smoking (data not shown).
The prevalence of CAD in type 2 diabetic patients by
tertiles of plasma NAMPT was 57% (T1), 67% (T2) and
75% (T3). Logistic regression analyses showed a positive
association of the highest tertile of plasma NAMPT with
CAD: OR 2.09, 95% CI 1.11 – 4.01, p = 0.02 (T3 vs T1);
OR 1.62, 95% CI 0.83 – 3.19, p = 0.15 (T3 vs T2) and OR
1.29, 95% CI 0.68 – 2.44, p = 0.42 (T2 vs T1; all compari-
sons adjusted for sex and age). NAMPT levels were not
significantly different in non-diabetic subjects with or
without CAD: 4.81 ± 3.00 ng/ml vs 5.25 ± 2.97 ng/ml, re-
spectively (p = 0.14).
Clinical characteristics of subjects by tertiles of plasma
NAMPT and glycemic status are shown in Table 2. Non-
diabetic subjects in the highest tertile had lower BMI,
lower levels of HbA1c, LDL cholesterol and triglycerides,
and higher levels of total adiponectin. These clinical pa-
rameters were not significantly different across tertiles of
Table 2 Clinical characteristics by tertiles of plasma NAMPT and glycemic status in Brazilian cohort
Subjects without type 2 diabetes p Type 2 diabetes subjects p
T1 T2 T3 T1 T2 T3
N 98 106 97 100 92 101
Plasma NAMPT(ng/ml) 3.06 ± 0.74 5.02 ± 0.56a 8.87 ± 2.92ab <0.0001 3.10 ± 0.73 5.00 ± 0.50a 8.67 ± 2.90ab <0.0001
(0.57 – 4.13) (4.14 – 6.05) (6.08 – 19.92) (0.93 – 4.13) (4.14 – 6.03) (6.08 – 20.18)
Age (y) 57 ± 10 59 ± 11 59 ± 11 0.31 59 ± 9 61 ± 10 64 ± 10a 0.01
Sex (male) 58 58 67 0.32 46 61 51 0.11
BMI (kg/m2) 26.8 ± 4.3 25.6 ± 4.2 25.3 ± 4.4a 0.04c 28.5 ± 5.3 27.5 ± 4.6 28.2 ± 4.5 0.31c
Waist circumference (cm) 97 ± 12 90 ± 14 92 ± 12 0.05c 102 ± 12 98 ± 12 99 ± 12 0.19c
Fasting Plasma Glucose (mmol/l) 5.6 ± 0.6 5.5 ± 0.6 5.4 ± 0.5 0.07 8.6 ± 3.7 8.1 ± 3.0 7.9 ± 2.6 0.38
HbA1c (%) 5.8 ± 0.4 5.9 ± 0.4 5.7 ± 0.4ab 0.004 7.7 ± 1.7 7.6 ± 1.6 7.8 ± 1.8 0.78
LDL cholesterol (mmol/l) 2.77 ± 0.89 2.86 ± 0.93 2.59 ± 0.95 0.05 2.40 ± 0.79 2.58 ± 1.01 2.55 ± 0.92 0.62
HDL cholesterol (mmol/l) 0.98 ± 0.25 1.04 ± 0.28 1.01 ± 0.28 0.45 1.04 ± 0.28 0.98 ± 0.29 1.00 ± 0.30 0.29
Triglycerides (mmol/l) 1.85 ± 1.53 1.54 ± 0.69 1.38 ± 0.68a 0.002 1.96 ± 1.22 1.94 ± 1.09 1.67 ± 0.94a 0.05
Total adiponectin (μg/ml) 8.8 ± 6.1 10.4 ± 6.9 11.2 ± 7.8a 0.006c 8.4 ± 5.5 8.3 ± 8.1 8.5 ± 6.2 0.82c
Arterial hypertension (%) 87 81 87 0.44 96 100 95 0.15
eGFR (ml/min) 87 ± 21 87 ± 25 86 ± 22 0.89 84 ± 24 82 ± 29 84 ± 28 0.56
Prevalence of CAD (%) 77 64 70 0.15 57 67 75 0.02
Antihypertensive medication (%)
ACEi 50 44 42 0.52 61 71 65 0.31
ARB 12 14 13 0.92 17 10 10 0.23
BB 41 48 40 0.47 57 52 54 0.48
Antidiabetic medication (%)
MTF – – – – 46 45 41 0.79
SU – – – – 27 22 23 0.75
INS – – – – 22 20 33 0.10
Data expressed as mean ± SD (and range, for plasma NAMPT levels). Statistics for quantitative parameters are ANOVA or ANCOVA with log-transformed data.
Tukey Kramer HSD test following ANOVA/ANCOVA: significantly different (p < 0.05) from T1 (a) or T2 (b). Comparison adjusted for age and sex (c). eGFR estimated
glomerular filtration rate, UAE urinary albumin excretion rate, ACEi angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, BB beta-blocker
MTF metformin, SU sulfonylurea, INS insulin.
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ceride levels that were also lower in subjects in highest
tertile. NAMPT levels were similar in subjects with or
without type 2 diabetes (4.97 ± 3.07 vs 4.99 ± 2.77, re-
spectively, p = 0.92; mean ± SD, ANCOVA with log-
transformed data, adjusted for sex, age and BMI) and no
association of NAMPT tertiles with diabetes was ob-
served (data not shown).
NAMPT rs9770242 and CAD
Genotype frequencies of rs9770242 by CAD status in both
cohorts are shown in Table 3. The prevalence of CAD by
genotype in the Brazilian cohort was 55% (GG), 66% (TG)
and 70% (TT) suggesting a possible codominant effect for
the T-allele. We observed in the Brazilian cohort a nom-
inal association of the T-allele with CAD (OR 1.36, 95% CI
1.01 – 1.86, p = 0.05, in a codominant model, adjusted for
sex, age and glycemic status). A more robust association
was observed with further adjustment for BMI, bloodpressure, dyslipidemia, and NAMPT levels (OR 1.46,
95% CI 1.06 – 2.01, p = 0.02). There was trend towards
higher plasma NAMPT levels in carriers of the risk T-
allele: 4.82 ± 1.99 (GG), 5.88 ± 2.87 (TG), 5.49 ± 2.81 ng/
ml (TT), mean ± SD, p = 0.11 adjusted for age and sex.
No genotype association with CAD was observed in the
North-American cohort (OR 1.02, 95% CI 0.76 – 1.22,
p = 0.85, in a codominant model for the T-allele, ad-
justed for sex and age). Similarly, no association was ob-
served when considering only those cases (n = 190) that
had a previous history of myocardial infarction (OR
1.09, 95% CI 0.78-1.32, p = 0.51).
Discussion
NAMPT has emerged in the last few years as a novel
adipokine potentially implicated in the pathogenesis of
atherosclerosis. Studies in different populations, including
a meta-analysis, suggested that high levels of circulating
NAMPT are positively associated with cardiovascular
Table 3 Genotype and allele frequencies of rs9770242 by CAD status
N rs9770242 OR (95% CI) P
MAF TT TG GG
Brazilian cohort
Without CAD 188 0.245 0.582 (n = 109) 0.351 (n = 66) 0.067 (n = 13) 1
With CAD 406 0.201 0.639 (n = 259) 0.323 (n = 131) 0.038 (n = 16) 1.36 (1.01 – 1.86)a 0.05
1.46 (1.06 – 2.01)b 0.02
North-American cohort
Without CAD 434 0.247 0.562 (n = 244) 0.383 (n = 166) 0.055 (n = 24) 1
With CAD 424 0.245 0.543 (n = 230) 0.424 (n = 180) 0.033 (n = 14) 1.02 (0.76 – 1.22)c 0.73
OR (odds ratio) in a codominant model for the T-allele determined in logistic regression analyses.(a)Adjusted for sex, age and glycemic status; (b)adjusted for sex,
age, glycemic status, BMI, blood pressure, dyslipidemia and NAMPT levels; (c)adjusted for age and sex. MAF: minor allele frequency. Hardy-Weinberg equilibrium:
Brazilian cohort, without CAD (p = 0.49), with CAD (p = 0.91); North-American cohort, without CAD (p = 0.54), with CAD (p = 0.003).
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types, as well as with the 10-year CVD Framingham risk
score [3,6,11,21-23]. The pathophysiological basis for
the association between NAMPT levels and CAD is still
unclear, as both cardioprotection [24-27] and deleteri-
ous effects of NAMPT on the cardiovascular system
have been reported [28-33].
In the present investigation, we confirmed the associ-
ation of high plasma NAMPT levels with CAD in the
subset of subjects with type 2 diabetes of the Brazilian
cohort, while no association with CAD was observed in
non-diabetic subjects. We have no clear explanation for
these heterogeneous results. The mechanisms of possible
interactions between NAMPT levels and glycemic status
on the risk of CAD cannot be assessed in our study,
given its observational nature. However, it is noteworthy
that non-diabetic subjects in the highest tertile of plasma
NAMPT levels had a more favorable profile of other car-
diovascular risk factors, compared to subjects in the
lowest tertile. They had lower BMI, lower levels of
HbA1c, LDL cholesterol and triglycerides, and higher
levels of total adiponectin. Adiponectin was shown to
have protective effects in the initiation and progression
of atherosclerosis by means of direct anti-inflammatory
and anti-atherogenic mechanisms [34-36]. So it is pos-
sible to speculate that higher adiponectin levels observed
in non-diabetic subjects would protect against the dele-
terious effects of higher NAMPT levels. No differences
in other cardiovascular risk factors by NAMPT tertiles
were observed in diabetic subjects, except for levels of
triglycerides. Interestingly, de Luis and coworkers also
observed an inverse correlation of NAMPT levels with
weight, fat mass and level of triglycerides in Spanish
non-diabetic obese subjects [2]. However, in that study
higher NAMPT levels were associated with higher LDL-
cholesterol and lower adiponectin levels. Differences in
ethnicity, glycemic and/or ponderal status and use of
medications in different studies could explain these het-
erogeneous results.We observed an association of the T-allele of rs9770242
SNP with CAD in the Brazilian cohort. There was trend
towards higher plasma NAMPT levels in carriers of the
risk T-allele, but the allelic association with CAD was inde-
pendent of plasma NAMPT levels. It is noteworthy that
the same allele was shown to be associated with higher in-
sulin and glucose plasma levels and increased visceral/sub-
cutaneous fat NAMPT mRNA expression ratio [14,15].
NAMPT is located both intracellularly and extracellularly
[37]. The intracellular pool of NAMPT may better reflect
NAMPT effects on tissues than the extracellular pool [38].
Moreover, it is unclear whether intracellular NAMPT re-
flects plasma NAMPT concentrations, or if does not,
whether there is a genotype-related effect on NAMPT
intracellular concentrations. Descriptions of genotype-
related effect on plasma NAMPT levels are still scarce. For
instance, Wang and co-authors showed that the C allele of
the -1535C >T polymorphism (rs61330082) in the
NAMPT gene was associated with proinflammatory status
and increased NAMPT levels [39].
The allelic association was not replicated in the North-
American cohort. Differences in cohort composition could
account for these heterogeneous genetic results. Subjects
in the Brazilian cohort, individually and/or as a group, had
mixed ethnic background, while the North-American co-
hort was composed of non-Hispanic white subjects only.
Moreover, the Brazilian cohort included both subjects with
or without type 2 diabetes, whereas North-American co-
hort included only subjects with type 2 diabetes. Selection
criteria of subjects without CAD were also different in
both cohorts. It was based on coronary angiography in the
Brazilian cohort, whereas it was based on clinical data in
the North American cohort. There was a slightly excess of
heterozygotes and a deficit of GG homozygotes among
CAD patients in the North-American cohort, resulting in
a nominally significant deviation from Hardy-Weinberg
equilibrium (HWE) in this group (Table 3 footnote). As
we carefully excluded the possibility of obvious genotyping
errors, the lack of HWE could be due to chance or may be
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cases, which would be consistent with the association of
the allele T with CAD in the Brazilian sample. Thus, we
cannot completely exclude the possibility that the absence
of allelic association with CAD in the North-American co-
hort may reflect a type 2 error (false negative results). Fi-
nally, we cannot also exclude the possibility that allelic
association with CAD in the Brazilian cohort may only re-
flect a type 1 error (false positive results) due to popula-
tion stratification. Data from the literature on NAMPT
genotypes and CAD-related traits are scarce. A study in a
Swedish cohort reported an association with myocardial
infarction of the G allele of the rs1319501, a promoter SNP
that is in complete linkage disequilibrium with rs9770242
[40]. Another study, but in a very particular population of
Spanish patients with rheumatoid arthritis reported no as-
sociation of rs9770242 with cardiovascular events or with
carotid artery intima-media thickness [41]. The T allele of
the rs9770242 and other SNPs in the NAMPT gene were
shown to be associated with fasting plasma insulin and glu-
cose levels in French-Canadian [14]. The genetic mechan-
ism behind these allelic associations is unclear. It is
noteworthy that rs9770242 is in complete linkage disequi-
librium with rs1319501 in the promoter of NAMPT, and
that the region surrounding and including rs1319501
matches the binding site for CREB (cAMP response
element-binding protein) transcription factors (http://asp.
ii.uib.no:8090/cgi-bin/CONSITE/consite/). The rs9770242
and other SNPs in the NAMPT gene were shown to be as-
sociated with visceral/subcutaneous NAMPT mRNA ex-
pression ratio in German subjects [15]. However, there was
strong linkage disequilibrium between the SNPs and the
functional variant was not identified.
Conclusion
Our results suggest that high plasma NAMPT levels are as-
sociated with CAD in subjects with type 2 diabetes and that
the NAMPT rs9770242 polymorphism may be associated
with CAD in some populations. Additional studies in larger
populations and based on extended haplotypes are needed
to confirm the association of NAMPT variants with CAD.
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